Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The Role of ADME Pharmacogenomics in Early Clinical Trials: Perspective of the Industry Pharmacogenomics Working Group (I-PWG)

30 Nov 2015

Abstract excerpt

Genetic polymorphisms in metabolizing enzymes and drug transporters have been shown to significantly impact the exposure of drugs having a high dependence on a single mechanism for their absorption, distribution or clearance, such that genotyping can lead to actionable steps in disease treatment. Recently, global regulatory agencies have provided guidance for assessment of pharmacogenomics during early stages of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Transport and Resistance Mechanisms
Share to Pharmacogenetics and Drug Metabolism
Share to Pharmacological Effects and Toxicity Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 26616152
DOI: 10.2217/pgs.15.141

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Role of ADME Pharmacogenomics in Early Clinical Trials: Perspective of the Industry Pharmacogenomics Working Group (I-PWG)PMID 26616152Read ↗

PhRMA white paper on ADME pharmacogenomics.Semantic proximity Read ↗

Assessment of drug metabolism enzyme and transporter pharmacogenetics in drug discovery and early development: perspectives of the I-PWG.Semantic proximity Read ↗

ADME pharmacogenetics: current practices and future outlook.Semantic proximity Read ↗

In vitro ADME phenotyping in drug discovery: current challenges and future solutions.Semantic proximity Read ↗

Circulating Biomarkers Instead of Genotyping to Establish Metabolizer Phenotypes.Semantic proximity Read ↗

Pharmacogenomics of drug-metabolizing enzymes: a recent update on clinical implications and endogenous effectsSemantic proximity Read ↗

Impact of drug transporter pharmacogenomics on pharmacokinetic and pharmacodynamic variability - considerations for drug development.Semantic proximity Read ↗

Pharmacogenomic Profiling of ADME Gene Variants: Current Challenges and Validation PerspectivesSemantic proximity Read ↗

Pharmacogenomics and adverse drug reactions in diagnostic and clinical practice.Semantic proximity Read ↗

Application of Pharmacogenomics in Clinical PharmacologySemantic proximity Read ↗

Development of a broad-based ADME panel for use in pharmacogenomic studies.Semantic proximity Read ↗

The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.